-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
- Operating income increased by 28.
- IFRS gross profit increased by 24.
- The company has given full play to the advantages of its “integrated, end-to-end” R&D service platform, and the synergy among various business segments has been further enhanced, enabling global customers to accelerate drug R&D
- Laboratory services in China: Start business continuity plans in time to turn crises into opportunities
- CDMO service revenue: recover the lost time in the first quarter through accelerating growth
- Laboratory services in the United States: without fear of the impact of the epidemic, firm long-term strategic goals, continue to invest and build new capabilities and new production capacity
-
-
- The company's US laboratory provides CTDMO services for 36 clinical-stage cell and gene therapy projects, including 24 phase I clinical trials and 12 phase II/III clinical trials
- Clinical research and other CRO services: Overcome the impact of the epidemic, maintain growth and continue the strong order increase trend
-
-
- Orders in hand have achieved rapid growth
- In September 2020, the company acquired Mingjie Pharmaceuticals to further integrate and expand the company's drug quality analysis service scale, and provide a full range of drug quality analysis and testing services from registration to production release for a diversified customer group
- In September 2020, the company acquired Mingjie Pharmaceuticals to further integrate and expand the company's drug quality analysis service scale, and provide a full range of drug quality analysis and testing services from registration to production release for a diversified customer group
- Orders in hand have achieved rapid growth
-
- The company's US laboratory provides CTDMO services for 36 clinical-stage cell and gene therapy projects, including 24 phase I clinical trials and 12 phase II/III clinical trials
-
- The company has given full play to the advantages of its “integrated, end-to-end” R&D service platform, and the synergy among various business segments has been further enhanced, enabling global customers to accelerate drug R&D
- IFRS gross profit increased by 24.
